Linked Life Data

10801287

Source:http://linkedlifedata.com/resource/pubmed/id/10801287

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10801287rdf:typepubmed:Citationlld:pubmed
pubmed-article:10801287lifeskim:mentionsumls-concept:C0160390lld:lifeskim
pubmed-article:10801287lifeskim:mentionsumls-concept:C0253023lld:lifeskim
pubmed-article:10801287lifeskim:mentionsumls-concept:C0023810lld:lifeskim
pubmed-article:10801287lifeskim:mentionsumls-concept:C1456820lld:lifeskim
pubmed-article:10801287lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:10801287pubmed:issue5lld:pubmed
pubmed-article:10801287pubmed:dateCreated2000-6-8lld:pubmed
pubmed-article:10801287pubmed:abstractTextTumor necrosis factor (TNF)-alpha and Fas ligand (FasL) are trimeric proteins that induce apoptosis through similar caspase-dependent pathways. Hepatocytes are particularly sensitive to inflammation-induced programmed cell death, although the contribution of TNF-alpha and/or FasL to this injury response is still unclear. Here, we report that D-galactosamine and lipopolysaccharide-induced liver injury in C57BL/6 mice is associated with increased hepatic expression of both TNF-alpha and FasL mRNA. Pretreatment of mice with a TNF-binding protein improved survival, reduced plasma aspartate aminotransferase concentrations, and attenuated the apoptotic liver injury, as determined histologically and by in situ 3' OH end labeling of fragmented nuclear DNA. In contrast, pretreatment of mice with a murine-soluble Fas fusion protein (Fasfp) had only minimal effect on survival, and apoptotic liver injury was either unaffected or exacerbated depending on the dose of Fasfp employed. Similarly, mice with a spontaneous mutation in FasL (B6Smn.C3H-Fasl(gld) derived from C57BL/6) were equally sensitive to D-galactosamine/lipopolysaccharide-induced shock. We conclude that the shock and apoptotic liver injury after D-galactosamine/lipopolysaccharide treatment are due primarily to TNF-alpha release, whereas increased FasL expression appears to contribute little to the mortality and hepatic injury.lld:pubmed
pubmed-article:10801287pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:languageenglld:pubmed
pubmed-article:10801287pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:citationSubsetIMlld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801287pubmed:statusMEDLINElld:pubmed
pubmed-article:10801287pubmed:monthMaylld:pubmed
pubmed-article:10801287pubmed:issn0363-6119lld:pubmed
pubmed-article:10801287pubmed:authorpubmed-author:CopelandE...lld:pubmed
pubmed-article:10801287pubmed:authorpubmed-author:MoldawerL LLLlld:pubmed
pubmed-article:10801287pubmed:authorpubmed-author:EdwardsC...lld:pubmed
pubmed-article:10801287pubmed:authorpubmed-author:MacKayS LSLlld:pubmed
pubmed-article:10801287pubmed:authorpubmed-author:KsontiniRRlld:pubmed
pubmed-article:10801287pubmed:authorpubmed-author:TannahillC...lld:pubmed
pubmed-article:10801287pubmed:authorpubmed-author:JosephsM DMDlld:pubmed
pubmed-article:10801287pubmed:authorpubmed-author:SolorzanoC...lld:pubmed
pubmed-article:10801287pubmed:authorpubmed-author:FukuzukaKKlld:pubmed
pubmed-article:10801287pubmed:authorpubmed-author:BahjatF RFRlld:pubmed
pubmed-article:10801287pubmed:issnTypePrintlld:pubmed
pubmed-article:10801287pubmed:volume278lld:pubmed
pubmed-article:10801287pubmed:ownerNLMlld:pubmed
pubmed-article:10801287pubmed:authorsCompleteYlld:pubmed
pubmed-article:10801287pubmed:paginationR1196-201lld:pubmed
pubmed-article:10801287pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:meshHeadingpubmed-meshheading:10801287...lld:pubmed
pubmed-article:10801287pubmed:year2000lld:pubmed
pubmed-article:10801287pubmed:articleTitleLipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-alpha and not by Fas ligand.lld:pubmed
pubmed-article:10801287pubmed:affiliationDepartment of Surgery, University of Florida College of Medicine, Gainesville, Florida 32610, USA.lld:pubmed
pubmed-article:10801287pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10801287pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801287lld:pubmed